Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone – Additional data from a phase 3 trial

尼妥珠单抗 医学 生活质量(医疗保健) 头颈部癌 随机对照试验 内科学 顺铂 放射治疗 肿瘤科 临床试验 癌症 外科 化疗 表皮生长因子受体 护理部
作者
Nandini Menon,Vijay Patil,Vanita Noronha,Amit Joshi,Atanu Bhattacharjee,Balajirao J Satam,Vijayalakshmi Mathrudev,Sarbani Ghosh Laskar,Kumar Prabhash
出处
期刊:Oral Oncology [Elsevier BV]
卷期号:122: 105517-105517 被引量:15
标识
DOI:10.1016/j.oraloncology.2021.105517
摘要

The addition of Nimotuzumab to radical chemoradiation (CRT) improved outcomes in patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) undergoing radical CRT in a phase 3 randomized trial. The current study focuses on the quality of life (QoL) of patients in this trial. In this phase III randomized trial, patients with newly diagnosed, nonmetastatic, stage III/IV LAHNSCC of the oral cavity, oropharynx, hypopharynx, or larynx were randomized to receive cisplatin 30 mg/m2 or cisplatin 30 mg/m2 with nimotuzumab once a week with curative radiotherapy. The primary end point of the trial was PFS. The aim of the current study was to compare the QoL between the two arms. QoL was assessed using the EORTC QLQ-C30 (v3.0) and HN-35 (v1.0). The linear mixed-effects model was used for longitudinal analysis of QoL. 536 patients were randomized in this trial (268 in each arm) and 423 patients were included for QoL analysis. There was a significant change in the global health status QoL scores over time (p = 0.0016) with no difference between the two arms (p = 0.396). On longitudinal analysis there was a significant difference in the QoL scores in most of the function & symptom scales over time, but there was no significant difference in these scores between the two arms. QoL scores for most symptom scales worsened during treatment and improved thereafter in both arms. The addition of nimotuzumab to cisplatin based chemoradiation in LAHNSCC improved PFS, LRC and DFS without negatively impacting QoL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
柳行天完成签到 ,获得积分10
2秒前
科目三应助阳光易真采纳,获得30
7秒前
yoyo发布了新的文献求助10
7秒前
思源应助Wl采纳,获得10
9秒前
共享精神应助橘笙采纳,获得10
10秒前
耍酷问兰发布了新的文献求助10
11秒前
科研通AI2S应助nczpf2010采纳,获得10
13秒前
搜集达人应助杜兰特工队采纳,获得10
18秒前
热心市民小红花应助牛马采纳,获得10
20秒前
热心市民小红花应助牛马采纳,获得10
20秒前
20秒前
Ava应助WJM采纳,获得10
24秒前
科研通AI2S应助nczpf2010采纳,获得10
25秒前
酷酷飞烟发布了新的文献求助10
25秒前
Bressanone发布了新的文献求助10
27秒前
李健的小迷弟应助老吴采纳,获得10
27秒前
大气的雅山完成签到,获得积分10
29秒前
shaoshao86完成签到,获得积分10
35秒前
35秒前
华仔应助科研通管家采纳,获得10
35秒前
逆时针应助科研通管家采纳,获得10
35秒前
MchemG应助科研通管家采纳,获得10
35秒前
研友_VZG7GZ应助科研通管家采纳,获得10
35秒前
wang应助科研通管家采纳,获得10
35秒前
wang应助科研通管家采纳,获得10
35秒前
ding应助科研通管家采纳,获得10
35秒前
上官若男应助科研通管家采纳,获得10
36秒前
思源应助科研通管家采纳,获得10
36秒前
田様应助科研通管家采纳,获得10
36秒前
小北发布了新的文献求助10
36秒前
NexusExplorer应助Quinna采纳,获得10
38秒前
39秒前
39秒前
量子星尘发布了新的文献求助10
41秒前
WJM发布了新的文献求助10
45秒前
老吴发布了新的文献求助10
46秒前
47秒前
佳语妍说完成签到,获得积分10
48秒前
49秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989069
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253589
捐赠科研通 3269939
什么是DOI,文献DOI怎么找? 1804851
邀请新用户注册赠送积分活动 882074
科研通“疑难数据库(出版商)”最低求助积分说明 809073